Anna DeFazio

List of Publications by Year
in descending order

211 papers	21,167 citations	28190 55 h-index	10424 139 g-index
224 all docs	224 docs citations	224 times ranked	27703 citing authors

#	Article	IF	Citations
1	Patterns of somatic mutation in human cancer genomes. Nature, 2007, 446, 153-158.	13.7	2,802
2	Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 2007, 447, 1087-1093.	13.7	2,165
3	International network of cancer genome projects. Nature, 2010, 464, 993-998.	13.7	2,114
4	Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome. Clinical Cancer Research, 2008, 14, 5198-5208.	3.2	1,312
5	Whole–genome characterization of chemoresistant ovarian cancer. Nature, 2015, 521, 489-494.	13.7	1,206
6	*BRCA* Mutation Frequency and Patterns of Treatment Response in *BRCA* Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2012, 30, 2654-2663.	0.8	1,018
7	Mutation of *FOXL2* in Granulosa-Cell Tumors of the Ovary. New England Journal of Medicine, 2009, 360, 2719-2729.	13.9	706
8	Driver mutations in *TP53* are ubiquitous in high grade serous carcinoma of the ovary. Journal of Pathology, 2010, 221, 49-56.	2.1	617
9	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. Journal of Clinical Investigation, 2013, 123, 517-25.	3.9	462
10	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
11	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	5.1	335
12	Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas. Clinical Cancer Research, 2009, 15, 1417-1427.	3.2	266
13	Dose-Response Association of CD8[+] Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	3.4	260
14	IL6-STAT3-HIF Signaling and Therapeutic Response to the Angiogenesis Inhibitor Sunitinib in Ovarian Clear Cell Cancer. Clinical Cancer Research, 2011, 17, 2538-2548.	3.2	217
15	Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. International Journal of Cancer, 2008, 122, 170-176.	2.3	205
16	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	5.8	192
17	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PLoS ONE, 2011, 6, e18064.	1.1	172
18	Immunohistochemical detection of proliferating cells in vivo.. Journal of Histochemistry and Cytochemistry, 1987, 35, 571-577.	1.3	154

#	Article	IF	Citations
19	Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment Outcome. Clinical Cancer Research, 2012, 18, 5806-5815.	3.2	150
20	Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation.. Molecular Endocrinology, 1995, 9, 1804-1813.	3.7	148
21	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. Oncotarget, 2015, 6, 37663-37677.	0.8	142
22	Germline Mutation in <i>BRCA1</i> or <i>BRCA2</i> and Ten-Year Survival for Women Diagnosed with Epithelial Ovarian Cancer. Clinical Cancer Research, 2015, 21, 652-657.	3.2	138
23	Inhibition of AP-1 binding and transcription by gold and selenium involving conserved cysteine residues in Jun and Fos.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 4497-4501.	3.3	137
24	Evidence of Gene–Environment Interactions between Common Breast Cancer Susceptibility Loci and Established Environmental Risk Factors. PLoS Genetics, 2013, 9, e1003284.	1.5	136
25	Multiple ABCB1 transcriptional fusions in drug resistant high-grade serous ovarian and breast cancer. Nature Communications, 2019, 10, 1295.	5.8	133
26	High resolution melting for mutation scanning of TP53exons 5–8. BMC Cancer, 2007, 7, 168.	1.1	119
27	Subtype–specific mutation of <i>PPP2R1A</i> in endometrial and ovarian carcinomas. Journal of Pathology, 2011, 223, 567-573.	2.1	114
28	Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2015, 113, 817-826.	2.9	111
29	The molecular origin and taxonomy of mucinous ovarian carcinoma. Nature Communications, 2019, 10, 3935.	5.8	110
30	Mutation of ERBB2 Provides a Novel Alternative Mechanism for the Ubiquitous Activation of RAS-MAPK in Ovarian Serous Low Malignant Potential Tumors. Molecular Cancer Research, 2008, 6, 1678-1690.	1.5	108
31	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	107
32	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.4	100
33	Genomic Classification of Serous Ovarian Cancer with Adjacent Borderline Differentiates RAS Pathway and <i>TP53</i>-Mutant Tumors and Identifies <i>NRAS</i> as an Oncogenic Driver. Clinical Cancer Research, 2014, 20, 6618-6630.	3.2	96
34	Recreational Physical Activity and Epithelial Ovarian Cancer: A Case-Control Study, Systematic Review, and Meta-analysis. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2321-2330.	1.1	92
35	Caring for women with ovarian cancer in the last year of life: A longitudinal study of caregiver quality of life, distress and unmet needs. Gynecologic Oncology, 2014, 132, 690-697.	0.6	92
36	<i>ABCB1</i> (<i>MDR 1</i>) Polymorphisms and Progression-Free Survival among Women with Ovarian Cancer following Paclitaxel/Carboplatin Chemotherapy. Clinical Cancer Research, 2008, 14, 5594-5601.	3.2	90

#	Article	IF	Citations
37	A Myc Activity Signature Predicts Poor Clinical Outcomes in Myc-Associated Cancers. Cancer Research, 2017, 77, 971-981.	0.4	90
38	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	5.8	88
39	Prevalence and predictors of anxiety and depression in women with invasive ovarian cancer and their caregivers. Medical Journal of Australia, 2010, 193, S52-7.	0.8	82
40	Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer. Clinical Cancer Research, 2018, 24, 569-580.	3.2	79
41	Subnuclear Distribution of Progesterone Receptors A and B in Normal and Malignant Endometrium. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1429-1442.	1.8	78
42	Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. International Journal of Cancer, 2005, 117, 1049-1054.	2.3	78
43	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	5.8	78
44	Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> Mutations. Clinical Cancer Research, 2013, 19, 3474-3484.	3.2	76
45	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	2.9	76
46	Strategies to enable large-scale proteomics for reproducible research. Nature Communications, 2020, 11, 3793.	5.8	75
47	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	2.3	73
48	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium€. Human Molecular Genetics, 2011, 20, 4693-4706.	1.4	71
49	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	1.3	70
50	Expression of Progesterone Receptors A and B in the Mouse Ovary during the Estrous Cycle. Endocrinology, 2004, 145, 3487-3494.	1.4	69
51	Association Between Single-Nucleotide Polymorphisms in Hormone Metabolism and DNA Repair Genes and Epithelial Ovarian Cancer: Results from Two Australian Studies and an Additional Validation Set. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 2557-2565.	1.1	65
52	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
53	MRP2 (ABCC2) and cisplatin sensitivity in hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 2006, 100, 239-246.	0.6	58
54	Overlapping and Distinct Expression of Progesterone Receptors A and B in Mouse Uterus and Mammary Gland during the Estrous Cycle. Endocrinology, 2006, 147, 5503-5512.	1.4	58

#	Article	IF	Citations
55	Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients. Clinical Cancer Research, 2011, 17, 5490-5500.	3.2	57
56	The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. British Journal of Cancer, 2008, 98, 1085-1093.	2.9	56
57	<i>EIF1AX</i> and <i>NRAS</i> Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas. Cancer Research, 2017, 77, 4268-4278.	0.4	56
58	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. Gynecologic Oncology, 2013, 131, 8-14.	0.6	55
59	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.4	54
60	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	2.9	54
61	Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. Journal of Pathology, 2021, 253, 41-54.	2.1	54
62	Reducing Time to Diagnosis Does Not Improve Outcomes for Women With Symptomatic Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, 2011, 29, 2253-2258.	0.8	52
63	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. BMC Medicine, 2015, 13, 156.	2.3	51
64	Expression of Progesterone Receptor A and B Isoforms in Low-grade Endometrial Stromal Sarcoma. International Journal of Gynecological Pathology, 2004, 23, 138-144.	0.9	50
65	Body size and risk of epithelial ovarian and related cancers: A population-based case-control study. International Journal of Cancer, 2008, 123, 450-456.	2.3	49
66	MAL2 and tumor protein D52 (TPD52) are frequently overexpressed in ovarian carcinoma, but differentially associated with histological subtype and patient outcome. BMC Cancer, 2010, 10, 497.	1.1	49
67	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.4	49
68	PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors. Gynecologic Oncology, 2019, 154, 531-538.	0.6	49
69	Therapeutic options for mucinous ovarian carcinoma. Gynecologic Oncology, 2020, 156, 552-560.	0.6	49
70	Prevalence and predictors of insomnia in women with invasive ovarian cancer: Anxiety a major factor. European Journal of Cancer, 2009, 45, 3262-3270.	1.3	48
71	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility "Hot-Spot". PLoS Genetics, 2010, 6, e1001016.	1.5	48
72	Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. American Journal of Clinical Nutrition, 2015, 102, 109-114.	2.2	48

#	Article	IF	Citations
73	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British Journal of Cancer, 2009, 100, 412-420.	2.9	47
74	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	3.2	47
75	Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS). Gynecologic Oncology, 2014, 133, 16-22.	0.6	47
76	Improved ovarian cancer EMT-CTC isolation by immunomagnetic targeting of epithelial EpCAM and mesenchymal N-cadherin. Journal of Circulating Biomarkers, 2018, 7, 184945441878261.	0.8	47
77	Focal Subnuclear Distribution of Progesterone Receptor Is Ligand Dependent and Associated with Transcriptional Activity. Molecular Endocrinology, 2007, 21, 14-29.	3.7	44
78	Association of a Common AKAP9 Variant With Breast Cancer Risk: A Collaborative Analysis. Journal of the National Cancer Institute, 2008, 100, 437-442.	3.0	44
79	Physical symptoms, coping styles and quality of life in recurrent ovarian cancer: A prospective population-based study over the last year of life. Gynecologic Oncology, 2013, 130, 162-168.	0.6	43
80	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	3.2	43
81	Acquired *RAD51C* Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian Carcinoma. Cancer Research, 2021, 81, 4709-4722.	0.4	42
82	Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2016, 115, 95-101.	2.9	39
83	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. American Journal of Human Genetics, 2020, 107, 837-848.	2.6	39
84	Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line - a potential mechanism for paclitaxel-mediated sparing of carboplatin-induced thrombocytopenia. Cancer Chemotherapy and Pharmacology, 2001, 48, 229-234.	1.1	38
85	Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. Oncogene, 2015, 34, 485-495.	2.6	38
86	FKBPL-based peptide, ALM201, targets angiogenesis and cancer stem cells in ovarian cancer. British Journal of Cancer, 2020, 122, 361-371.	2.9	38
87	Comparison of Expression Profiles in Ovarian Epithelium In Vivo and Ovarian Cancer Identifies Novel Candidate Genes Involved in Disease Pathogenesis. PLoS ONE, 2011, 6, e17617.	1.1	36
88	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. British Journal of Cancer, 2016, 114, 417-426.	2.9	35
89	Going to extremes: determinants of extraordinary response and survival in patients with cancer. Nature Reviews Cancer, 2019, 19, 339-348.	12.8	35
90	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35

#	Article	IF	Citations
91	Skewed X Chromosome Inactivation and Breast and Ovarian Cancer Status: Evidence for X-Linked Modifiers of BRCA1. Journal of the National Cancer Institute, 2008, 100, 1519-1529.	3.0	33
92	Ankyrin Repeat Domain 1, *ANKRD1*, a Novel Determinant of Cisplatin Sensitivity Expressed in Ovarian Cancer. Clinical Cancer Research, 2008, 14, 6924-6932.	3.2	33
93	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
94	Expression and tyrosine phosphorylation of EMS1 in human breast cancer cell lines. , 1996, 68, 485-492.		32
95	Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance. Gynecologic Oncology, 2018, 150, 239-246.	0.6	32
96	Patterns of chemotherapy treatment for women with invasive epithelial ovarian cancer â€" A population-based study. Gynecologic Oncology, 2013, 129, 310-317.	0.6	30
97	Coping strategies, trajectories, and their associations with patient-reported outcomes among women with ovarian cancer. Supportive Care in Cancer, 2018, 26, 4133-4142.	1.0	29
98	Germline polymorphisms in an enhancer of *PSIP1* are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	0.8	29
99	History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes and Control, 2017, 28, 469-486.	0.8	28
100	Scientists and clinicians test their metalâ€"back to the future with platinum compounds. Lancet Oncology, The, 2002, 3, 312-318.	5.1	26
101	The RING finger domain E3 ubiquitin ligases BRCA1 and the RNF20/RNF40 complex in global loss of the chromatin mark histone H2B monoubiquitination (H2Bub1) in cell line models and primary high-grade serous ovarian cancer. Human Molecular Genetics, 2016, 25, ddw362.	1.4	26
102	Population-based targeted sequencing of 54 candidate genes identifies *PALB2* as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	1.5	26
103	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	1.1	26
104	Dietary folate and related micronutrients, folate-metabolising genes, and ovarian cancer survival. Gynecologic Oncology, 2014, 132, 566-572.	0.6	25
105	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	2.3	25
106	DNA of mouse mammary tumor virusâ€"like virus is present in human tumors influenced by hormones. Journal of Medical Virology, 2010, 82, 1044-1050.	2.5	24
107	Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer. Scientific Reports, 2014, 4, 4669.	1.6	24
108	Statin use and survival following a diagnosis of ovarian cancer: A prospective observational study. International Journal of Cancer, 2021, 148, 1608-1615.	2.3	24

#	Article	IF	Citations
109	Copy Number Aberrations in Benign Serous Ovarian Tumors: A Case for Reclassification?. Clinical Cancer Research, 2011, 17, 7273-7282.	3.2	23
110	New Approaches to Continuing Medical Education: a QStream (spaced education) Program for Research Translation in Ovarian Cancer. Journal of Cancer Education, 2017, 32, 476-482.	0.6	23
111	New therapeutic opportunities for women with low-grade serous ovarian cancer. Endocrine-Related Cancer, 2022, 29, R1-R16.	1.6	23
112	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
113	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	1.4	22
114	High Levels of Genomic Aberrations in Serous Ovarian Cancers Are Associated with Better Survival. PLoS ONE, 2013, 8, e54356.	1.1	22
115	Molecular Subclasses of Clear Cell Ovarian Carcinoma and Their Impact on Disease Behavior and Outcomes. Clinical Cancer Research, 2022, 28, 4947-4956.	3.2	22
116	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€"Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	1.6	21
117	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. Modern Pathology, 2021, 34, 194-206.	2.9	21
118	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	1.1	20
119	Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2017, 28, 459-468.	0.8	20
120	When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancer. Gynecologic Oncology, 2020, 159, 179-186.	0.6	20
121	Medical Costs and Outcomes for Australian Women With Ovarian Cancer: A Patient-Level Analysis Over 2.5 Years. International Journal of Gynecological Cancer, 2010, 20, 757-765.	1.2	19
122	Aspirin, nonaspirin nonsteroidal anti-inflammatory drugs, acetaminophen and ovarian cancer survival. Cancer Epidemiology, 2015, 39, 196-199.	0.8	19
123	<i>BRAF</i> Mutations in Low-Grade Serous Ovarian Cancer and Response to BRAF Inhibition. JCO Precision Oncology, 2018, 2, 1-14.	1.5	19
124	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. Nature Communications, 2021, 12, 1078.	5.8	19
125	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
126	PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. Journal of Gynecologic Oncology, 2019, 30, e86.	1.0	18

#	ARTICLE	IF	CITATIONS
127	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome. Gynecologic Oncology, 2016, 142, 458-464.	0.6	17
128	Paragon (ANZGOG-0903). International Journal of Gynecological Cancer, 2017, 27, 900-906.	1.2	17
129	Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer. Translational Oncology, 2017, 10, 346-356.	1.7	17
130	Insomnia and its association with quality of life in women with ovarian cancer. Gynecologic Oncology, 2020, 158, 760-768.	0.6	17
131	Inverse regulation of oestrogen receptor and epidermal growth factor receptor gene expression in MCF-7 breast cancer cells treated with phorbol ester. Journal of Steroid Biochemistry and Molecular Biology, 1996, 58, 267-275.	1.2	16
132	History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. British Journal of Cancer, 2017, 117, 1063-1069.	2.9	16
133	Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes and Control, 2019, 30, 537-547.	0.8	16
134	A healthy lifestyle and survival among women with ovarian cancer. International Journal of Cancer, 2020, 147, 3361-3369.	2.3	16
135	Helplessness/hopelessness, minimization and optimism predict survival in women with invasive ovarian cancer: a role for targeted support during initial treatment decision-making?. Supportive Care in Cancer, 2016, 24, 2627-2634.	1.0	15
136	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	0.9	15
137	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	0.6	15
138	Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	2.1	15
139	Rapid fluorometric detection of drug resistant tumour cells. British Journal of Cancer, 1985, 52, 633-636.	2.9	14
140	Accelerated Barocycler Lysis and Extraction Sample Preparation for Clinical Proteomics by Mass Spectrometry. Journal of Proteome Research, 2019, 18, 399-405.	1.8	14
141	Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. Gynecologic Oncology, 2018, 150, 527-533.	0.6	14
142	Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 229-232.	1.1	14
143	Modulation of antifolate cytotoxicity by metabolites from dying cells in a lymphocyte clonal assay. British Journal of Cancer, 1988, 57, 459-463.	2.9	13
144	Global gene expression profiles of ovarian surface epithelial cells in vivo. Journal of Molecular Endocrinology, 2008, 40, 281-296.	1.1	13

#	ARTICLE	IF	CITATIONS
145	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
146	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	2.9	13
147	Evaluating patient-reported symptoms and late adverse effects following completion of first-line chemotherapy for ovarian cancer using the MOST (Measure of Ovarian Symptoms and Treatment) Tj ETQq1 1 0.784314 rgBT1/Overlo		
148	Coordinate regulation of oestrogen and prolactin receptor expression by sodium butyrate in human breast cancer cells. Biochemical and Biophysical Research Communications, 1992, 182, 740-745.	1.0	12
149	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
150	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 132-141.	1.1	12
151	Quality of life and treatment response among women with platinum-resistant versus platinum-sensitive ovarian cancer treated for progression: A prospective analysis. Gynecologic Oncology, 2014, 132, 130-136.	0.6	11
152	High-Throughput Amplicon-Based Copy Number Detection of 11 Genes in Formalin-Fixed Paraffin-Embedded Ovarian Tumour Samples by MLPA-Seq. PLoS ONE, 2015, 10, e0143006.	1.1	11
153	Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer. JNCI Cancer Spectrum, 2018, 2, pky047.	1.4	11
154	<scp>ABCC4</scp>/<scp>MRP4</scp> contributes to the aggressiveness of Myc‐associated epithelial ovarian cancer. International Journal of Cancer, 2020, 147, 2225-2238.	2.3	11
155	Cell-free DNA is abundant in ascites and represents a liquid biopsy of ovarian cancer. Gynecologic Oncology, 2021, 162, 720-727.	0.6	11
156	Assessment of Multifactor Gene–Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	1.1	10
157	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1470-1473.	1.1	10
158	The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. Cellular Signalling, 2015, 27, 1763-1771.	1.7	9
159	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	1.1	9
160	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	2.9	9
161	Expression of steroid hormone receptors in BRCA1-associated ovarian carcinomas. Gynecologic Oncology, 2005, 97, 16-25.	0.6	8
162	Polymorphisms in the FGF2 Gene and Risk of Serous Ovarian Cancer: Results From the Ovarian Cancer Association Consortium. Twin Research and Human Genetics, 2009, 12, 269-275.	0.3	8

#	Article	IF	Citations
163	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 2012, 15, 615-623.	0.3	8
164	MCM3 is a novel proliferation marker associated with longer survival for patients with tubo-ovarian high-grade serous carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 855-871.	1.4	8
165	Increased prevalence of obstructive sleep apnea in women diagnosed with endometrial or breast cancer. PLoS ONE, 2021, 16, e0249099.	1.1	7
166	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	0.8	7
167	Evidence against the compartmentation of adenosine kinase and adenosine deaminase activities in human erythrocytes. FEBS Letters, 1980, 113, 215-217.	1.3	6
168	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	1.3	6
169	Pleiotropy-guided transcriptome imputation from normal and tumor tissues identifies candidate susceptibility genes for breast and ovarian cancer. Human Genetics and Genomics Advances, 2021, 2, 100042.	1.0	6
170	Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts. Frontiers in Neuroscience, 2021, 15, 700923.	1.4	6
171	Identification of a Locus Near *ULK1* Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	1.1	5
172	Mechanisms determining sensitivity to cisplatin in three mutant Chinese hamster ovary cell lines. Mutation Research DNA Repair, 1998, 407, 243-252.	3.8	4
173	The hidden burden of anxiety and depression in ovarian cancer: A prospective longitudinal study from diagnosis.. Journal of Clinical Oncology, 2018, 36, 10081-10081.	0.8	4
174	Cancer sleep symptom–related phenotypic clustering differs across three cancer specific patient cohorts. Journal of Sleep Research, 2022, 31, e13588.	1.7	4
175	Uncertainty and the unmet informational needs of patients with cancer of unknown primary (CUP): a cross-sectional multi-site study. Supportive Care in Cancer, 2022, 30, 8217-8229.	1.0	4
176	Enumeration of 6-thioguanine-resistant tumour cells using flow cytometry and comparison with a microtitration cloning assay. Mutation Research - Environmental Mutagenesis and Related Subjects Including Methodology, 1989, 216, 57-64.	0.4	3
177	Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer. Scientific Reports, 2018, 8, 1508.	1.6	3
178	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancer—A Multicenter Analysis. Cancers, 2022, 14, 1954.	1.7	3
179	Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 680-688.	1.1	2
180	Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines. , 2000, 87, 487.		2

#	Article	IF	Citations
181	Survival in patients with BRCA mutation-positive platinum-sensitive recurrent ovarian cancer.. Journal of Clinical Oncology, 2014, 32, e16519-e16519.	0.8	2
182	Getting the most out of follow-up: A prospective study using the Measure of Ovarian Symptoms and Treatment concerns (MOST) symptom index to evaluate and track adverse effects (AEs) and detect symptoms of recurrence in patients with ovarian cancer (OC) following first line chemotherapy (1LT).. Journal of Clinical Oncology, 2018, 36, 10062-10062.	0.8	2
183	Abstract A25: BRAFV600E mutations in serous ovarian cancer and response to the BRAF inhibitor, dabrafenib.. , 2016, , .		2
184	The Ovarian cancer Prognosis And Lifestyle (OPAL) study.. Journal of Clinical Oncology, 2018, 36, 88-88.	0.8	2
185	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	1.1	2
186	Germline BRCA variants, lifestyle and ovarian cancer survival. Gynecologic Oncology, 2022, , .	0.6	2
187	Regional Variation in Extracellular Purine Levels in Vivo. Advances in Experimental Medicine and Biology, 1984, 165 Pt A, 301-304.	0.8	1
188	Abstract A29: Loss of histone H2B monoubiquitination in ovarian cancer â€" new therapeutic targeting opportunities based on chromatin relaxation. , 2013, , .		1
189	Characterization of ovarian cancer long-term responders on olaparib.. Journal of Clinical Oncology, 2014, 32, 5534-5534.	0.8	1
190	Abstract 2761: Germline polymorphism discovered via a cell-based genome-wide approach predicts platinum response in ovarian and head and neck cancers. , 2010, , .		1
191	Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.. Journal of Clinical Oncology, 2016, 34, 5553-5553.	0.8	1
192	Quality of Life and Treatment Response Among Women With Platinum-Resistant Versus Platinum-Sensitive Ovarian Cancer Treated for Progression. Obstetrical and Gynecological Survey, 2014, 69, 257-259.	0.2	0
193	Tumour profiling for treatment of patients with ovarian cancers. Pathology, 2018, 50, S77.	0.3	0
194	Epithelial ovarian cancer: Genomic landscape and evolving precision treatment. , 2021, , 1-23.		0
195	1429Impact of BRCA mutation status and lifestyle factors on survival among women with ovarian cancer. International Journal of Epidemiology, 2021, 50, .	0.9	0
196	Abstract 1660: Cholesterol efflux transporter gene expression predicts clinical outcome in serous ovarian cancer. , 2011, , .		0
197	Abstract 3875: NUAK2, a gene with a putative driver mutation in ovarian cancer, is regulated through the murine estrus cycle and loss is associated with worse outcome in ovarian cancer. , 2011, , .		0
198	Abstract 4679: A multi-stage genome-wide association study on response to chemotherapy in ovarian cancer. , 2011, , .		0

#	Article	IF	Citations
199	Abstract A3: Mucinous ovarian tumors: Are they all the same?. , 2013, , .		0
200	Abstract A13: Molecular profiling of low grade serous ovarian tumors. , 2013, , .		0
201	Genome-wide association study for identification of candidate SNPs associated with carboplatin and paclitaxel clearance in ovarian cancer patients.. Journal of Clinical Oncology, 2014, 32, 5563-5563.	0.8	0
202	Abstract 3286: Identification of genetic loci associated with ovarian cancer prognosis. , 2014, , .		0
203	Abstract 4616: Chemo-sensitisation in epithelial ovarian cancer cell lines by targeting Ankyrin Repeat Domain 1 (ANKRD1). , 2014, , .		0
204	Abstract 313: Examining the role of ABCA1 cholesterol transporter in ovarian cancer spheroids. , 2015, , .		0
205	Abstract 5493: Genome-wide study of carboplatin and paclitaxel disposition in ovarian cancer patients. , 2015, , .		0
206	Abstract B08: Genomics analyses of less common epithelial ovarian cancer subtypes.. , 2016, , .		0
207	Abstract 2787: Identifying predictive markers of endocrine response in high-grade serous ovarian cancer using RNA sequencing. , 2017, , .		0
208	The hidden burden of anxiety and depression in ovarian cancer: A prospective study from diagnosis.. Journal of Clinical Oncology, 2018, 36, 155-155.	0.8	0
209	When will I feel normal again? Quality of life trajectories after first-line chemotherapy for ovarian cancer.. Journal of Clinical Oncology, 2018, 36, 172-172.	0.8	0
210	Abstract 225: Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis. , 2018, , .		0
211	Abstract 2584: Mutations in low-grade serous ovarian cancer and response toBRAFandMEKinhibitors. , 2018, , .		0